Background. The aim of this study was to evaluate in non-hypertensive children following renal transplantation (TX) the rates and determinants of transition to hypertension. Methods. Retrospective case note review of all current paediatric kidney transplant patients in the UK. At baseline (6 months following TX), all included subjects were non-hypertensive with systolic and/or diastolic clinic blood pressure (BP) ≤95th percentile while on no anti-hypertensive therapy. We assessed progression from optimal (systolic and/or diastolic clinic BP <50th percentile), normal (systolic and/or diastolic clinic BP ≥50th but <90th percentile) and pre-hypertension (systolic and/or diastolic clinic BP 90th-95th percentile) to hypertension (systolic and/or diastolic clinic BP >95th percentile). If systolic and diastolic BP levels belonged to different categories, the higher of the two levels were used for categorization. Results. At baseline, 146 of 524 (27.9%) children (106 male) median [inter-quartile range (IQR)] age 7.8 years (4.8, 11.8) were non-hypertensive and not on any anti-hypertensive therapy; there were 34 patients (23.2%) with optimal BP, 90 (61.6%) with normal BP and 22 (15.1%) with pre-hypertension. They were followed up for a median of 2.0 (1.0, 4.0) years post-TX. At the end of follow-up, BP was optimal in 37 patients (25.3%), normal in 35 (24.0%), high normal in 2 (1.4%) and 72 (49.3%) had progressed to hypertension. The Kaplan-Meier estimated time at which 50% of patients developed hypertension was 2.0 years for the pre-hypertension and 3.0 years in the normal BP group as opposed to 40% risk at 7-year post-TX in the optimal group (P = 0.001 between the three groups). The differences between BP groups remained significant after adjustment for all risk factors on multivariate analysis. Conclusions. Just over 49% of our initially nonhypertensive patients progressed to hypertension following TX. BP needs careful monitoring post-TX and ideally should be maintained in the 'normal' and 'optimal' range.
Introduction
Young adults with childhood-onset renal disease have an increased risk of mortality. The risk of cardiac death is increased almost 700 times in young adults with end-stage renal disease (ESRD) [1] , accounting for nearly 40% of all deaths. Young adults with childhood-onset ESRD exhibit mortality rates ∼30-fold higher than children with no renal disease [2, 3] . Although cardiac disease accounts for a fraction of mortality in children overall, for children with ESRD on dialysis, cardiovascular (CV) disease during childhood accounts for 20-25% of mortality [4, 5] . Restoration of renal function by transplantation reduces though does not eliminate this increased CV risk and CV disease remains one of the commonest causes of death in this cohort [6, 7] . In these young adults, it is likely that the onset of CV disease begins during childhood [8] .
Hypertension is a key risk factor contributing to this CV morbidity, is closely interlinked with chronic kidney disease, and is nearly always observed in ESRD [9] . Hypertension as a CV risk factor persists for several years following transplantation [10, 11] and contributes to the increased CV morbidity and mortality. The high prevalence rates of hypertension and the difficulty in achieving adequate blood pressure (BP) control highlight the importance of identifying any intervention that may lead to an improvement in the CV health post-transplantation [10] .
The Framingham investigators first demonstrated the transition of BP levels from normal to hypertensive state in a healthy adult population in the USA [12] . This phenomenon has now been reported from other large adult population-based studies in Europe [13, 14] , Asia [15, 16] and Mexico [17] .
To our knowledge, there is currently no data describing the phenomenon of progression from non-hypertension to hypertension in adult and paediatric patients following renal transplantation (TX). Understanding the factors that lead to elevation of BP in this population may lead to improved management. Our study aim was to evaluate in non-hypertensive children 6 months following kidney transplantation the rates and determinants of transition from non-hypertension to systolic and/or diastolic hypertension.
Materials and methods

Information governance
We undertook a nationwide review of BP levels in children following TX, on behalf of the British Association for Paediatric Nephrology (BAPN). This analysis was performed from data collected from this retrospective case note review. This was performed by visiting each paediatric nephrology unit in the UK and included all paediatric renal transplant patients with a functioning allograft. The audit proposal, objectives, data collection and analysis process were agreed upon by the UK Renal Registry Paediatric Audit & Registry subcommittee and approved by all members of the BAPN. Renal Registry leads at each centre facilitated authors L.K. and M.D.S. to obtain centre-specific audit committee approval and authorization to visit their centres. They also made case notes available for review at the time of the study visit.
Study population
The study population was of children and young adults under the age of 18 years, who had received a kidney-only transplant and were followed up in a paediatric nephrology centre in the UK. All of the following criteria were essential for inclusion in this analysis. At the time of an outpatient clinic visit 6 months following kidney transplantation, patients: (i) non-hypertensive, defined as systolic and/or diastolic clinic BP zscore ≤1.645 which corresponds with the 95th percentile, (ii) were not on any anti-hypertensive medication and (iii) had at least one further systolic blood pressure (SBP) and/or diastolic blood pressure (DBP) measurement available from a subsequent clinic visit ≥6 months later. We excluded those subjects: (i) who were >18 years of age or (ii) with no systolic and/or diastolic clinic BP measurement beyond the baseline BP measurement. We have described the time point at 6 months posttransplantation as 'baseline'.
Data collection method
Twelve of 13 paediatric nephrology centres in the UK were visited by either L.K. or M.D.S. over a 2-year period, between December 2005 and December 2007. Case note review was performed for every child who had a functioning renal transplant at the time of the centre visit. Data were collected from routine outpatient clinic visit, when the patient was stable, at pre-determined time points.
Data were collected at the following time points: (i) during the first year following transplantation at 6 and 12 months, (ii) at 6-month intervals thereafter until 5 years post-transplantation and (iii) once every subsequent year on the patient's transplant anniversary month. Data from any time point were only recorded if a clinic BP measurement had been recorded in the case notes. If there was no BP measurement available, no other data from this time point were recorded. If there was no clinic visit at the above time points, data from a clinic visit within 8 weeks of the time point were recorded. Any clinic visit beyond this time period was excluded and no data recorded for that time point.
For all patients, the following patient characteristics were recorded: age at transplantation, gender, ethnicity, allograft source (deceased or living donor), primary renal disease ('structural' such as renal cystic, dysplasia and obstructive uropathy or 'non-structural' such as glomerulonephritis), pre-emptive transplantation (yes/no) and mode and duration of dialysis pre-transplantation. In each patient at each time point, we recorded the systolic and/or diastolic clinic BP, height in centimetres, weight in kilograms, body mass index (BMI) expressed as kilogram per square metre, haemoglobin, creatinine, treatment with anti-hypertensive medication (yes/no) and immunosuppressive therapy. Creatinine was measured variably using Jaffé or the enzymatic method at each individual centre. This is because the method for measuring creatinine has changed from the Jaffé to the enzymatic method at each centre in the UK over the past decade but at varying time points.
The reference range for height, weight and BMI in childhood varies with gender and age. Height, weight and BMI were all adjusted for age and z-scores were calculated using British reference data [18] . Using UK Department of Health guidelines, we defined obesity ≥98th percentile (z-score ≥2.054), overweight between ≥91st and <98th percentile (zscore ≥1.341 and <2.054) and normal <91st percentile (z-score <1.341) [19] . Renal function was expressed as estimated glomerular filtration rate (eGFR) using the recent Schwartz formula [20] .
Measurement of BP
BP measurements were obtained from medical records of clinic attendances, while the patient received their routine clinical care. For each patient, BP measurements may have been performed by different members of the clinical team using different instruments. These included oscillometric instruments and mercury sphygmomanometers, aneroid instruments with auscultation or Doppler detection of SBP following occlusion. At the time of review, nine centres used oscillometric, two Doppler detection of SBP and one mercury or aneroid instruments. In some centres, clinicians often rechecked BP using mercury sphygmomanometers or aneroid instruments with auscultation if oscillometric BP levels were elevated on initial measurement. A single BP measurement was included at each time point. Where there were multiple recorded BP measurements at a time point, the lowest measurement was included.
Definition of level of BP
The reference range for BP varies with gender, age and height. Systolic and/or diastolic clinic BP measurements were therefore analysed as zscores using the criteria of the fourth report of the National High Blood Pressure Education Program (NHBPEP) Working Group in the USA [21] . Hypertension was defined as systolic and/or diastolic clinic BP >95th percentile (z-score >1.645) and non-hypertension as systolic and/ or diastolic clinic BP ≤95th percentile (≤1.645). At baseline and subsequently, we categorized non-hypertensive patients into three further subgroups based on their systolic and/or diastolic clinic BP z-score: (i) 'optimal', if it was <0.00 z-score. This would represent systolic and/or diastolic clinic BP <50th percentile, (ii) 'normal', if it was between 0.001 and +1.280 z-score. This would represent systolic and/or diastolic clinic BP ≥50th but <90th percentile and (iii) 'pre-hypertension', if it was between 1.281 and 1.645 z-score. This would represent systolic and/ or diastolic clinic BP between the 90th-95th percentile. If SBP and DBP levels belonged to different categories, the higher of the two levels was used for categorization.
The number of follow-up visits from baseline was 1, 2, 3, 4 and ≥5 in 41, 31, 17, 12 and 45 patients, respectively. The median [inter-quartile range (IQR)] number of systolic and/or diastolic clinic BP measurements for each subject was 4 (2, 7). On longitudinal follow-up from baseline of each patient, patients remaining normotensive were reclassified according to their systolic and/or diastolic clinic BP z-score at the time of their last outpatient clinic visit. Those becoming hypertensive were reclassified according to their systolic and/or diastolic clinic BP z-score at the first visit when they became hypertensive. Similarly, patients who remained normotensive but commenced anti-hypertensive therapy were reclassified at their first clinic visit after starting the treatment.
Statistical analysis
Data were expressed as mean ± SD, median and IQR or percentages with three-group comparisons via analysis of variance, Kruskal-Wallis tests and chi-square tests as appropriate. Kaplan-Meier survival estimates and hence crude incidence rates of hypertension were obtained for all subjects and also by baseline BP category. The log-rank test was used to test for differences between the groups. Unadjusted hazard ratios (HRs) for progression to hypertension for the three initial groups were obtained from univariate Cox proportional hazards models. Multivariate Cox models were used to obtain HRs adjusted for the following baseline characteristics: age (<12 or ≥12 years), gender, transplant vintage year (2001 or after versus 2000 or before), eGFR (>60 versus <60 mL/min/ 1.73 m 2 ), BMI z-score (grouped into obese, overweight or normal), whether they had dialysis pre-transplant and the allograft source (deceased or living donor). We used (unadjusted) Cox models with timedependent variables to assess whether: (i) the BMI z-score at each time point, (ii) the change in BMI z-score per month from baseline to the time point and (iii) the change in eGFR per month from baseline to the time point was related to the risk of progression to hypertension at that time point. All statistical analyses were performed using SAS version 9.2.
Results
Of the 564 patients <18 years of age with a functioning kidney transplant in December 2007 in the UK, we reviewed case notes of 524 patients from 12 centres. Systolic and/or diastolic clinic BP measurement at 6 months following transplantation was available in 428 of 524 subjects (83.8%). Two hundred and fifty of 428 subjects (58.4%) were on one or more anti-hypertensive medication. Of the 178 remaining subjects, 21 of 178 (11.8%) were hypertensive but not on any treatment and 11 had no further measurements. As these 32 subjects did not meet all the inclusion criteria, they were excluded from further analysis. This analysis therefore includes 146 of 524 subjects (27.9%) who at baseline were not hypertensive and not on any anti-hypertensive medications. The median (IQR) number of such patients at each centre was 8 (7, 22) .
Their median (IQR) age at baseline was 7.8 years (4.8, 11.8) and they were followed up for a median of 2.0 (1.0, 4.0) years post-transplantation. There were 22 (15.1%) in the pre-hypertension, 90 (61.6%) in the normal and 34 (23.2%) in the optimal group of non-hypertensive subjects at baseline.
Overall, 49.3% (72/146) of subjects became hypertensive (58/72) or were commenced on anti-hypertensive therapy (14/72) over the period of follow-up. The cumulative incidence rates [95% confidence interval (95% CI)] of hypertension were 37.7% (29.1, 45. Patient demographics are shown in Table 1 for all subjects and for the three subgroups. All subjects were on alternate day prednisolone in addition to other immunosuppressant medications. These included 78 patients on tacrolimus and azathioprine, 44 on cyclosporine A and azathioprine and 17 on other combinations [15 on calcineurin inhibitor (14 on tacrolimus; 1 on cyclosporine A) and mycophenolate mofetil (MMF); 1 patient each on cyclosporine A and MMF and MMF alone]. Details of immunosuppressive medications were not available for seven patients. Excluding those on any combination with MMF, patients on cyclosporine A-based immunosuppression were significantly more likely to have higher BP levels when compared with patients on tacrolimus (P = 0.02). Table 2 shows the changes in BP subgroups on longitudinal follow-up according to their baseline BP category. Fifty-eight subjects became hypertensive after 2 years and 66 subjects after 4 years of follow-up from baseline. Six further patients developed hypertension over the following 5 years of follow-up. The highest incidence of hypertension was observed in the pre-hypertension BP group. Figure 1 shows the Kaplan-Meier estimates of progression to hypertension from the prehypertension, normal and optimal BP groups at baseline. This shows that the estimated time at which half the people will have become hypertensive was 2.0 and 3.0 years for the pre-hypertension and normal BP groups, respectively. In the optimal BP group, even after a follow-up period of 7 years following transplantation, the estimated proportion becoming hypertensive remained <50%. Table 3 shows the systolic and diastolic clinic BP changes from baseline to last follow-up, by the three BP groups, in all patients who remained normotensive and off anti-hypertensive medication. Overall, for all patients who remained normotensive, there was an increase of 3 ± 12 mmHg but a decrease of 0.36 ± 1.05 SBP z-score. In contrast, patients who became hypertensive had an increase of 15 ± 11 mmHg and an increment of 1.07 ± 1.01 in their systolic clinic BP z-score (both P < 0.0001). The median (IQR) change from Table 1 . Demographics of all subjects at 6 months post-transplantation who were non-hypertensive (systolic and/or diastolic clinic BP ≤95th percentile) and separately in three subgroups: (i) pre-hypertension (systolic and/or diastolic clinic BP 90th-95th percentile), (ii) normal (systolic and/ or diastolic clinic BP 50th-90th percentile) and (iii) optimal (systolic and/or diastolic clinic BP <50th percentile) a
Demographics
All ( baseline SBP for the patients that became hypertensive was 8 (5, 10) mmHg for pre-hypertension, 16 (9, 22) mmHg for normal and 19 (14, 22) mmHg for optimal (P = 0.06). The rate of change in systolic clinic BP expressed in 'mmHg per year of follow-up from baseline' was most for the optimal group at 26 (5, 41), 16 (6, 26) for the normal and 6 (3, 20) for the pre-hypertension group (P = 0.47). We observed a fall in SBP over time in 20.5% (30/146) patients across all BP categories. Six patients in the pre-hypertension, 18 patients in the normal and six patients in the optimal group had a fall in their systolic clinic BP over time.
Overall, for all patients who remained normotensive, there was an increase of 3 ± 10 mmHg but a decrease of 0.12 ± 0.89 DBP z-score. In contrast, patients who became hypertensive had an increase of 12 ± 12 mmHg and an increment of 0.85 ± 1.05 in their diastolic clinic BP z-score (P = 0.0007 and P < 0.0001, respectively). The median (IQR) change from baseline DBP for the patients that became hypertensive was 5 (4, 20) mmHg for pre-hypertension, 10 (2, 20) mmHg for normal and 26 (24, 32) mmHg for optimal (P = 0.01). The rate of change in diastolic clinic BP expressed in 'mmHg per year of follow-up from baseline' was most for the optimal group at 32 (6, 48), 8 (2, 19) for the normal and 10 (3, 40) for the pre-hypertension group (P = 0.19). Six patients in the pre-hypertension, 10 patients in the normal and 2 patients in the optimal group had a fall in their diastolic clinic BP over time. Table 4 shows the results of the Cox proportional hazards models relating the key factors at baseline to progression to hypertension. The univariate (unadjusted) models gave HRs (95% CI) of progression to hypertension for the prehypertension and the normal BP group, each compared with the optimal BP group, of 3.79 (1.56, 9.19 ) and 2.68 (1.26, 5.70), respectively. These HRs in the adjusted model were 3.31 (1.33, 8.22) and 2.33 (1.06, 5.12), respectively. Of the evaluated factors, patients who were obese (versus normal BMI) had significant risk of progression to hypertension [HR 1.92 (1.06, 3.50), P = 0.03]. We were unable to identify any other significant relationship on univariate or multivariate models that related to progression to hypertension.
Determinants of progression to clinic hypertension
A further model was fitted with just BP group and immunosuppressant type as explanatory variables for those 122 people taking tacrolimus or cyclosporine A alone. Immunosuppressant type was not significantly related to progression to hypertension (P = 0.34) and adding it to the model had little effect on the HRs for BP group. From the models with time-dependent variables, there was weak evidence (P = 0.04) that the BMI z-score was related to progression with HR for 1-unit increase in BMI z-score of 1.22 (1.01, 1.48) but no evidence that the rate of change in BMI z-score or eGFR was significantly related to progression (P = 0.95 and 0.41, respectively).
Discussion
This is the first report in the renal transplant literature that describes the rates and determinants of transition from the non-hypertensive to hypertensive state in a cohort of children who have a high risk for future CV disease. The cumulative incidence rates of hypertension were 37.7% at 2 years and 49.3% at 4 years. The patients with the highest level of BP at baseline ( pre-hypertension group) exhibited the highest incident rates to become hypertensive (Figure 1) .
In otherwise healthy adult populations, this phenomenon of progression of BP levels is widely reported [12] [13] [14] [15] [16] [17] . Investigators of the Copenhagen MONICA cohort recently added to this evidence base by demonstrating the continuous relationship of BP level with adverse CV outcome in a previously healthy adult population [14] . They reported a doubling of 10-year CV risk a All subjects were normotensive and not on any anti-hypertensive medication throughout the period of follow-up until categorized as being 'hypertensive'. Fig. 1 . Kaplan-Meier plot of progression to hypertension based on status at 6 months following transplantation. Each line is curtailed when the number 'at risk' fell below five subjects. from 5.1% for the groups with optimal or normal level of BP without progression to 11.1 and 13.9% in the 'highnormal' or pre-hypertension BP and 'hypertension' groups with progression, respectively. This body of published data in individuals with no renal disease collectively emphasizes the risk of progression to hypertension from non-hypertensive BP levels and suggests that such a phenomenon is also likely to exist in a high-risk cohort such as children following TX.
There is a stepwise increase in the risk of progression to hypertension across the three non-hypertensive groups ( pre-hypertension, normal and optimal) in our study (Figure 1 ). This is similar to the Framingham study [12] findings and other adult reports [13, 14, 16] that describe this phenomenon of progression to hypertension in a previously non-hypertensive population. Sixty-four per cent of our patients in the pre-hypertension and 24% in the optimal group in our study became hypertensive (BP >95th percentile) over the period of follow-up. There was a 133 and 231% increased risk of developing hypertension for patients in the normal and pre-hypertension group when compared to the optimal group, respectively. By definition, patients in the pre-hypertension group needed a smaller increment of BP to progress to hypertension especially when compared to patients in the optimal group. In patients who developed hypertension, those in the optimal group compared with the patients in the normal and pre-hypertension groups, exhibited the maximal increase in BP level from baseline (P = 0.06 and P = 0.01 for SBP and DBP, respectively), although the A striking observation in our study is of the very high rates of incident hypertension over a very short period of follow-up when compared with reported incident rates of hypertension observed in the general adult and adolescent population. The Flemish study investigators [13] observed an incident rate of hypertension of 24.7% over an 8-year follow-up period in patients <50 years of age. Older subjects in their study had more than twice the incident rate (as compared to the younger population) over a similar period of follow-up. Zheng et al. [16] recently highlighted the rapidly evolving public health problem in rural China following observation of incident rates of hypertension at 26.5% over a 28-month median follow-up period in patients <50 years of age. In contrast, Tirosh et al. [22] observed an incident rate of hypertension of 1.1% after 8 years of follow-up and 16.1% after 25-years of follow-up in 23 191 older adolescents mean age of 17.4 years at baseline. The high incident rate of hypertension observed in our study therefore underscores the 'high risk' for future CV disease in this population, with the incident rate of hypertension in paediatric patients similar to that observed in adults >50 years of age.
Paediatric renal transplant recipients have a number of risk factors that lead to the high prevalence rates of hypertension [23] . A number of these factors are different to those reported as precursors of hypertension in the general adult population [24] . These include side effects of immunosuppressive medications (steroids and calcineurin inhibitors), graft dysfunction as a result of acute rejection or interstitial fibrosis and tubular atrophy, increased weight gain following transplantation, recurrent primary disease in the allograft and pyelonephritis. It is therefore not surprising that following transplantation, there is an amplification of rates of hypertension in this population. Patients on cyclosporine A had higher BP levels at baseline but neither cyclosporine nor tacrolimus influenced the patient's progression to hypertension subsequently. Previous studies examining the influence of calcineurin inhibitor agents in adults and children following TX have reported on prevalence rates of hypertension only and not on the level of BP in children who are nonhypertensive [25] [26] [27] [28] . It is possible that observed differences in level of BP and rates of progression to hypertension may be related to blood levels of calcineurin inhibitor agents [29] but we did not collect this information in our patients.
We found no differences between the three non-hypertensive groups in the distribution of gender or ethnicity. Both male gender and increasing ponderosity have been shown to increase significantly the risk of developing hypertension in adolescents and adults [22, 30] . It is possible that the observed stepwise increase in the risk of progression to hypertension between the groups may be a result of risk factors for hypertension not recorded in this study, including demographic factors [12] (e.g. family history of hypertension) and laboratory parameters such as cholesterol, serum glucose, insulin resistance and biomarkers of inflammation [14] . As has been discussed previously [16] , other potential reasons for the increased rates in the pre-hypertension group may include more risk factors for hypertension. Both obesity and rapidly increasing BMI have been shown in the general paediatric population to have a significant influence on future CV disease [31] , with concerns of similar effects in children following TX [4] . Similarly, increasing BMI has a significant influence on progression to hypertension in previously normotensive adults [15, 16] . We found no significant difference in BMI z-scores between patients in the three non-hypertensive subgroups at baseline, but patients with obese (versus normal BMI) at baseline had an additional significant risk of progression to hypertension ( Table 4 ).
The strengths of this study are that it includes >90% of the children with functioning kidney transplants in the UK, that data were collected by investigators searching individual case records and that the majority of patients had at least four BP measurements 6 months apart available for analysis. Shortcomings include its retrospective nature and small patient numbers. It is possible that patients may have been misclassified at baseline as single BP measurements were taken to categorize patients to hypertensive and 'non-hypertensive' groups. We also accept that variation in methods for BP measurements and the differing BP instruments in use at different centres are an important limitation to our findings. BP values obtained using different measurement techniques (aneroid, Doppler, oscillometric and sphygmomanometer) may not be comparable. Ideally, a standard technique for the measurement of BP would have been desirable but this was not possible given the retrospective nature of this study. It is important also to highlight here that creatinine values were measured using different methods (Jaffé or enzymatic) at variable time points across different centres during the study period. Unfortunately, it has not been possible to precisely determine the method of measurement of creatinine at all different time points in this cohort. This may have implications for the conclusions we have drawn regarding the relationship of eGFR with BP levels. Finally, it should be noted that clinic BP alone without any information regarding 24-h ambulatory BP monitoring data will be unable to diagnose nocturnal hypertension, which has been shown to be the predominant form of hypertension in this cohort [32] .
Our results provide an insight into the progression of clinic BP levels in this cohort. Patients with pre-hypertension or non-optimal BP levels in the non-hypertensive range are at most risk of developing hypertension. Individuals at risk of development of hypertensive disease can thus be identified early. We believe that the findings of this study have important implications for the current recommendations on the level of BP to be achieved in this population. A reduction in incident rates of hypertension could be achieved by aiming for lower levels of BP in the normal and optimal range.
